Gå direkt till innehåll

Kategorier: covid vaccine

  • Björn Sjöstrand, CEO Scandinavian Biopharma; Magnus Sävenhed, Managing Director Novavax SE; Jörgen Persson, Head of Customer Engagement and Market Access Europe Novavax; Jonas Bengtsson, VP Business Development Scandinavian Biopharma

    Scandinavian Biopharma enters into a commercial collaboration with Novavax in Sweden

    Scandinavian Biopharma and Novavax have signed a commercial collaboration agreement for the Covid vaccine Nuvaxovid. As of October 2022, the company is the representative for Nuvaxovid on the Swedish market and will assist Novavax with the sales and marketing of the vaccine. Nuvaxovid is an adjuvanted protein-based vaccine that protects against SARS Covid-19.